Citations

Showing 10 of 108162 citations.

Impact of Advanced Renal Dysfunction on Posttransplant Outcomes After Living Donor Liver Transplantation in the United States
Bittermann, Therese, Abt, Peter L., Olthoff, Kim M., Kaur, Navpreet, Heimbach, Julie K., Emamaullee, Juliet, Emamaullee, Juliet , Bittermann, Therese, Abt, Peter L., Olthoff, Kim M., Kaur, Navpreet, Heimbach, Julie K.

Mayo Clinic

Transplantation | March 4, 2021 | Volume: 105 | Issue: 12 | Pages: 2564-2570

10.1097/tp.0000000000003728 | PMID 33660658 Get It

Background. Survival after living donor liver transplantation (LDLT) in the United States is excellent. However, the significance of pretransplant kidney disease on outcomes in this population is poorly understood. Methods. This was a retrospective cohort study of 2806 LDLT recipients nationally between January 2010 and June 2020. Recipients with estimated glomerular filtration rate <40 mL/min/1.73 m2 (eGFR-low) or requiring dialysis were compared. Multivariable survival analyses evaluated (1) eGFR-low as a predictor of post-LDLT survival and (2) the survival of LDLT versus deceased donor liver transplant (DDLT) alone with eGFR-low. Results. From 2010 to 2020, 140 (5.0%) patients had eGFR-low and 18 (0.6%) required dialysis pre-LDLT. The number of LDLTs requiring dialysis between 2017 and 2020 outnumbered the prior 7 y. Overall LDLT experience was greater at centers performing LDLT in recipients with renal dysfunction (P < 0.001). LDLT recipients with eGFR-low had longstanding renal dysfunction: mean eGFR 3–6 mo before LDLT 42.7 (±15.1) mL/min/1.73 m2. Nearly half (5/12) of eGFR-low recipients with active kidney transplant (KT) listing at LDLT experienced renal recovery. Five patients underwent early KT after LDLT via the new “safety net” policy. Unadjusted survival after LDLT was worse with eGFR-low (hazard ratio 2.12 versus eGFR ≥40 mL/min/1.73 m2; 95% confidence interval, 1.47-3.05; P < 0.001), but no longer so when accounting for mean eGFR 3–6 mo pre-LDLT (hazard ratio, 1.27; 95% confidence interval, 0.82-1.95; P = 0.3). The adjusted survival of patients with eGFR-low receiving LDLT versus deceased donor liver transplant alone was not different (P = 0.08). Conclusions. Overall, outcomes after LDLT with advanced renal dysfunction are acceptable. These findings are relevant given the recent “safety net” KT policy.
Electrocardiogram screening for aortic valve stenosis using artificial intelligence
Cohen‐Shelly, Michal , Attia, Zachi I. , Friedman, Paul A. , Essayagh, Benjamin A, Ko, Wei-Yin, Murphree, Dennis H. , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Carter, Rickey E. , Oh, Jae K. , Ito, Saki , Enriquez-Sarano, Maurice , Murphree, Dennis H , Michelena, Hector I , Carter, Rickey E , Johnson, Patrick W , Lopez-Jimenez, Francisco , Attia, Zachi I , Essayagh, Benjamin , Johnson, Patrick W. , Noseworthy, Peter A. , López-Jiménez, Francisco

Mayo Clinic

European Heart Journal | March 4, 2021 | Volume: 42 | Issue: 30 | Pages: 2885-2896

10.1093/eurheartj/ehab153 | PMID 33748852 Get It

Abstract Aims Early detection of aortic stenosis (AS) is becoming increasingly important with a better outcome after aortic valve replacement in asymptomatic severe AS patients and a poor outcome in moderate AS. We aimed to develop artificial intelligence-enabled electrocardiogram (AI-ECG) using a convolutional neural network to identify patients with moderate to severe AS. Methods and results Between 1989 and 2019, 258 607 adults [mean age 63 ± 16.3 years; women 122 790 (48%)] with an echocardiography and an ECG performed within 180 days were identified from the Mayo Clinic database. Moderate to severe AS by echocardiography was present in 9723 (3.7%) patients. Artificial intelligence training was performed in 129 788 (50%), validation in 25 893 (10%), and testing in 102 926 (40%) randomly selected subjects. In the test group, the AI-ECG labelled 3833 (3.7%) patients as positive with the area under the curve (AUC) of 0.85. The sensitivity, specificity, and accuracy were 78%, 74%, and 74%, respectively. The sensitivity increased and the specificity decreased as age increased. Women had lower sensitivity but higher specificity compared with men at any age groups. The model performance increased when age and sex were added to the model (AUC 0.87), which further increased to 0.90 in patients without hypertension. Patients with false-positive AI-ECGs had twice the risk for developing moderate or severe AS in 15 years compared with true negative AI-ECGs (hazard ratio 2.18, 95% confidence interval 1.90–2.50). Conclusion An AI-ECG can identify patients with moderate or severe AS and may serve as a powerful screening tool for AS in the community.
Relapsed/Refractory International Prognostic Index (R/ R‐IPI ): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma
Maurer, Matthew J. , Jakobsen, Lasse Hjort , Mwangi, Raphael , Schmitz, Norbert , Farooq, Umar , Flowers, C. R., Brown, Peter de Nully , Thompson, Carrie A. , Frederiksen, Henrik , Cunningham, David , Jørgensen, Judit , Poeschel, Viola, Nowakowski, Grzegorz S. , Seymour, John F. , Ghesquières, Hervé , Ziepert, Marita , Tilly, Hervé , Salles, Gilles , Shi, Qian , Joergensen, Judit Mészáros , Maurer, Matthew , Farooq, Umar , Shi, Qian , Salles, Gilles A , Frederiksen, Henrik , Cunningham, David , de Nully Brown, Peter , Merli, Francesco , Haïoun, Corinne , El‐Galaly, Tarec Christoffer , Habermann, Thomas M.

Mayo Clinic

American Journal of Hematology | March 4, 2021 | Volume: 96 | Issue: 5 | Pages: 599-605

10.1002/ajh.26149 | PMID 33661547 Get It

Abstract Disease progression after frontline therapy for Diffuse large B‐cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time‐dependent concordance indices (c‐statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post‐progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post‐progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR‐T therapy as well as trial designs. The model is available in smartphone‐based point of care applications.
Prediction of Death After Noncardiac Surgery: Potential Advantage of Using High‐Sensitivity Troponin T as a Continuous Variable
Machado, Maurício de Nassau , Rodrigues, Fernando Bruetto , Nakazone, Marcelo Arruda , Martin, Danilo F., Sabbag, Amália Tieco Rocha, Grigolo, Ingrid Hellen, Silva‐Júnior, Osvaldo L., Maia, Lília Nigro , Jaffe, Allan S. , Martin, Danilo Fernando , Grigolo, Ingrid Helen, Jaffe, Allan S.

Mayo Clinic

Journal of the American Heart Association | March 4, 2021 | Volume: 10 | Issue: 6 | Pages: No page available

10.1161/jaha.120.018008 | PMID 33660524 Get It

Background Increased high‐sensitivity cardiac troponin T (hs‐cTnT) above the upper reference limit (URL) after noncardiac surgery identifies patients at risk for mortality. Prior studies have not analyzed hs‐cTnT as a continuous variable or probed age‐ and sex‐specific URLs. This study compared the prediction of 30‐day mortality using continuous postoperative hs‐cTnT levels to the use of the overall URL and age‐ and sex‐specific URLs. Methods and Results Patients (876) >40 years of age who underwent noncardiac surgery were included. Hs‐cTnT was measured on postoperative day 1. Cox proportional hazards models were used to compare associations between 30‐day mortality and using hs‐cTnT as a continuous variable, or above the overall or age‐ and sex‐specific URLs. Comparisons were performed by the area under the receiver operating characteristic curve analysis. Mortality was 4.2%. For each 1 ng/L increase in postoperative hs‐cTnT, there was a 0.3% increase in mortality ( P <0.001). Patients with postoperative hs‐cTnT >14 ng/L were 37% of the cohort, while those above age‐ and sex‐specific URLs were 25.3%. Both manifested higher mortality (hazard ratio [HR], 3.19; 95% CI, 1.20–8.49; P =0.020) and (HR, 2.76; P =0.009) than those with normal levels. The area under receiver operating characteristic curve was 0.89 using hs‐cTnT as a continuous variable, 0.87 for age‐ and sex‐specific URLs, and 0.86 for the overall URL. Conclusions Hs‐cTnT as a continuous variable was independently associated with 30‐day mortality and had the highest accuracy. Hs‐cTnT elevations using overall and/or age‐ and sex‐specific URLs were also associated with higher mortality.
Holmium Laser Enucleation of the Prostate: A Description of the Fundamental Skills
Narang, Gopal , Abdul-Muhsin, Haidar , Humphreys, Mitchell R. , Cheney, Scott, Moore, Jonathan

Mayo Clinic

Videourology™ | March 4, 2021 | Volume: 35 | Issue: 4 | Pages: No page available

10.1089/vid.2020.0132 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2020.0132.M1 sj-vid-1-vid-10.1089_vid.2020.0132
Salvage ablation for locally recurrent prostate cancer
Lomas, Derek J. , Woodrum, David A. , Mynderse, Lance A.

Mayo Clinic

Current Opinion in Urology | March 4, 2021 | Volume: 31 | Issue: 3 | Pages: 188-193

10.1097/mou.0000000000000861 | PMID 33660620 Get It

Purpose of review This review aims to summarize the latest evidence for the use of salvage ablation of localized prostate cancer recurrences after primary therapy radiotherapy or prostatectomy. Recent findings Savage ablation represents a treatment option in select patients with localized recurrences following primary therapy of prostate cancer. Following radiotherapy, salvage cryotherapy and high-intensity focused ultrasound (HIFU) demonstrate encouraging oncologic outcomes. Biochemical recurrence-free survival ranged from 71% at 2 years to 44.2% at 10 years for cryotherapy and from 51% at 5 years to 28.7% at 10 years for HIFU. Rates of adverse effects appear to be more favorable with ablation compared to salvage surgery. Focal salvage ablation may offer a further balance between oncologic control and adverse effects. Following radical prostatectomy, recent data on the use of salvage ablation of local recurrences are less robust with only a few small studies published in the last 2 years. Summary Salvage ablation is an option for localized disease recurrences following primary treatment. Its role is most established for postradiation recurrence. It can also be utilized in postprostatectomy recurrence, although published data is more limited. Future studies are needed to further explore the role of ablation in both cohorts.
Outcomes Associated With Norepinephrine Use Among Cardiac Intensive Care Unit Patients with Severe Shock
Burstein, Barry , Vallabhajosyula, Saraschandra , Ternus, Bradley , Murphree, Dennis H. , Barsness, Gregory W. , Murphree, Dennis, Vallabhajosyula, Saraschandra , Kashani, Kianoush , Jentzer, Jacob C.

Mayo Clinic

Shock | March 4, 2021 | Volume: 56 | Issue: 4 | Pages: 522-528

10.1097/shk.0000000000001767 | PMID 34524266 Get It

ABSTRACT Background: Recent data suggests improved outcomes among cardiac intensive care unit (CICU) patients treated with norepinephrine, especially patients with severe shock. We aimed to describe the association between norepinephrine and mortality in CICU patients with severe shock, defined as those requiring high-dose vasopressors (HDV). Materials and Results: We retrospectively evaluated Mayo Clinic CICU patients treated with vasopressors from 2007 to 2015. HDV was defined as a peak Cumulative Vasopressor Index of four for any vasopressor. Peak norepinephrine equivalent (NEE) dose was used to compare vasopressor doses. Multivariable logistic regression was used to determine predictors of hospital mortality. Results: We included 2,090 patients with a median age of 69 years (IQR 59–78), including 35% females; 44% of patients received HDV. Hospital mortality was higher among patients receiving HDV (42% vs. 16%, unadjusted OR 3.87, 95% CI 3.16–4.75, P < 0.01). On multivariable analysis in HDV patients, hospital mortality increased with rising peak NEE (adjusted OR 1.02 per 0.01 mcg/kg/min, 95% CI 1.01–1.02, P < 0.01) and the use of NE was associated with lower hospital mortality (adjusted OR 0.46, 95% CI 0.31–0.72, P < 0.01). After adjustment for illness severity, peak NEE and norepinephrine use were not associated with mortality among patients who did not require HDV. Conclusions: Mortality is high among CICU patients requiring HDV, and rises with increasing vasopressor requirements. Use of NE was associated with lower mortality among patients requiring HDV, but not among those without HDV, implying that patients with more severe shock may benefit from preferential use of NE.
Basing Information on Comprehensive, Critically Appraised, and Up-to-Date Syntheses of the Scientific Evidence: An Update from the International Patient Decision Aid Standards
Hoffmann, Tammy , Bakhit, Mina , Durand, Marie‐Anne , Saunders, Catherine , Brito, Juan P. , Hoffmann, Tammy C , Brito, Juan P , Perestelo‐Pérez, Lilisbeth

Mayo Clinic

Medical Decision Making | March 4, 2021 | Volume: 41 | Issue: 7 | Pages: 755-767

10.1177/0272989x21996622 | PMID 33660539 Get It

Background Patients and clinicians expect the information in patient decision aids to be based on the best available research evidence. The objectives of this International Patient Decision Aid Standards (IPDAS) review were to 1) check the currency of, and where needed, update evidence for the domain of “basing the information in decision aids on comprehensive, critically appraised, and up-to-date syntheses of the evidence”; 2) analyze the evidence characteristics of decision aids; and 3) propose updates to relevant IPDAS criteria. Methods We searched MEDLINE and PubMed to inform updates of this domain’s definitions, justifications, and components. We also searched 5 sources to identify all publicly available decision aids ( N = 471). Two assessors independently extracted each aid’s evidence characteristics. Results Minor updates to the definitions and theoretical justifications of this IPDAS domain are provided and changes to relevant IPDAS criteria proposed. Nearly all aids (97%) provided a year of creation/update, but most (81%) did not report an explicit update or expiration policy. No scientific references were cited in 33% of aids. Of the 314 that cited at least 1 reference, 39% cited at least 1 guideline, 44% cited at least 1 systematic review, and 23% cited at least 1 randomized trial. In 35%, it was unclear what statement in the aid the citations referred to. Only 14% reported any of the processes used to find and decide on evidence inclusion. Only 14% reported the evidence quality. Many emerging issues and future research areas were identified. Conclusions Although many emerging issues need to be addressed, this IPDAS domain is validated and criteria refined. High-quality patient decision aids should be based on comprehensive and up-to-date syntheses of critically appraised evidence.
Attitude Toward Family Involvement in End-of-Life Care Among Older Chinese Americans: How Do Family Relationships Matter?
Wang, Kaipeng , Sun, Fei , Liu, Yanqin , Kong, Dexia , Fries, Carson M. De

Mayo Clinic

Journal of Applied Gerontology | March 4, 2021 | Volume: 41 | Issue: 2 | Pages: 380-390

10.1177/0733464821996865 | PMID 33660545 Get It

Family involvement is critical to end-of-life (EOL) care among older adults. This study aims to examine the association and pathways between family relationships and older Chinese Americans’ attitude toward family involvement in EOL care discussions. Data were collected from 260 Chinese Americans aged 55 years and above. Structural equation modeling was used to examine the total and indirect effects of family relationships on attitude toward family involvement in discussing EOL care plans. Family relationships had a significant positive total effect on attitude toward family involvement in EOL care. Indirect effects of family relationships on attitude toward family involvement in EOL care through self-efficacy, perceived benefits, and perceived barriers of discussing EOL care with family members were all significant. Findings provide empirical evidence of how family relationships affect older Chinese Americans’ attitude toward family involvement in EOL care and underline the need for family-centered EOL interventions for this population.
Training the Trainer: Preparing Anesthesiology Residents to be Trainers in the Operating Room
Huang, Jeffrey , Licatino, Lauren K. , Sims, Charles R. , Licatino, Lauren

Mayo Clinic

MedEdPORTAL | March 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11116 | PMID 33768148 Get It